Anti-cancer effects of 20(S)-protopanoxadiol on human acute lymphoblastic leukemia cell lines Reh and RS4;11

Medical Oncology

Volumn 28, Issue 3, 2011, Pages 813-821

  Sun, Lihua ^a   Wang, Qiong ^a   Liu, Xinmin ^a,b   Brons, Nicolaas H C ^b   Wang, Ning ^b   Steinmetz, André ^b   Lv, Yali ^a   Liao, Yonghong ^a   Zheng, Huyong ^c  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

20(S) protopanoxadiol (PPD); Acute lymphoblastic leukemia (ALL); Cell cycle; Differentiation; IC 50

Indexed keywords

20 (S) PROTOPANOXADIOL; ANTINEOPLASTIC AGENT; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL DIFFERENTIATION; CYTOTOXICITY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SAPOGENINS;

EID: 80052444053     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9508-1     Document Type: Article

References (45)

1. CL Sawyers CT Denny ON Witte 1991 Leukemia and the disruption of normal hematopoiesis Cell 64 337 350 1988151 10.1016/0092-8674(91)90643-D 1:CAS:528:DyaK3MXpvFWktQ%3D%3D
2. KC Oeffinger MM Hudson 2004 Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors CA Cancer J Clin 54 208 236 15253918 10.3322/canjclin.54.4.208
3. AK Fielding, et al. 2007 Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study Blood 109 944 950 17032921 10.1182/blood-2006-05-018192 1:CAS:528:DC%2BD2sXjtFersbg%3D
4. HG Einsiedel, et al. 2005 Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin- Frankfurt-Munster Group 87 J Clin Oncol 23 7942 7950 16258094 10.1200/JCO.2005.01.1031
5. V Mihal, et al. 2004 The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol Bull Cancer 91 E80 E89 15562558
6. DR Parkinson SG Arbuck T Moore JM Pluda MC Christian 1994 Clinical development of anticancer agents from natural products Stem Cells 12 30 43 7908243 10.1002/stem.5530120108 1:STN:280:DyaK2c7ptFGmtA%3D%3D
7. GM Cragg PG Grothaus DJ Newman 2009 Impact of natural products on developing new anti-cancer agents Chem Rev 109 3012 3043 19422222 10.1021/cr900019j 1:CAS:528:DC%2BD1MXlsFCns7Y%3D
8. GM Cragg DJ Newman 2009 Nature: a vital source of leads for anticancer drug development Phytochem Rev 8 313 343 10.1007/s11101-009-9123-y 1:CAS:528:DC%2BD1MXmtlKnurc%3D
9. AS Attele JA Wu CS Yuan 1999 Ginseng pharmacology: multiple constituents and multiple actions Biochem Pharmacol 58 1685 1693 10571242 10.1016/S0006-2952(99)00212-9 1:CAS:528:DyaK1MXntVCgtbw%3D
10. YZ Xiang HC Shang XM Gao BL Zhang 2008 A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials Phytother Res 22 851 858 18567057 10.1002/ptr.2384
11. YS Chang EK Seo C Gyllenhaal KI Block 2003 Panax ginseng: a role in cancer therapy? Integr Cancer Ther 2 13 33 12941165 10.1177/1534735403251167 1:CAS:528:DC%2BD3sXit1ymsr0%3D
12. H Dang, et al. 2009 Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression Prog Neuropsychopharmacol Biol Psychiatry 33 1417 1424 19632285 10.1016/j.pnpbp.2009. 07.020 1:CAS:528:DC%2BD1MXhtlygtb%2FI
13. JD Park DK Rhee YH Lee 2005 Biological activities and chemistry of saponins from Panax ginseng C. A. Meyer Phytochem Rev 4 159 175 10.1007/s11101-005-2835-8 1:CAS:528:DC%2BD28Xht1Wjsrg%3D
14. W Wang, et al. 2008 Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides Prostate 68 809 819 18324646 10.1002/pros.20742 1:CAS:528:DC%2BD1cXnsVKktrg%3D
15. HC Ren, et al. 2008 Sensitive determination of 20(S)-protopanaxadiol in rat plasma using HPLC-APCI-MS: application of pharmacokinetic study in rats J Pharm Biomed Anal 48 1476 1480 19022601 10.1016/j.jpba.2008.09.045 1:CAS:528:DC%2BD1MXntlynsQ%3D%3D
16. Hao M, et al. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS ONE 2008;3:e2697.
17. Y Yu Q Zhou Y Hang XX Bu W Jia 2007 Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells Cancer 109 2374 2382 17464948 10.1002/cncr.22659 1:CAS:528:DC%2BD2sXmvVKjsbo%3D
18. SH Oh BH Lee 2004 A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage Toxicol Appl Pharmacol 194 221 229 14761678 10.1016/j.taap.2003.09.011 1:CAS:528:DC%2BD2cXptVamtA%3D%3D
19. C Rosenfeld, et al. 1977 Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line Nature 267 841 843 197411 10.1038/267841a0 1:STN:280:DyaE2s3lsFSlsQ%3D%3D
20. RC Stong SJ Korsmeyer JL Parkin DC Arthur JH Kersey 1985 Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics Blood 65 21 31 3917311 1:STN:280: DyaL2M%2Fntlalsw%3D%3D
21. B Peng, et al. 2008 Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis Gynecol Oncol 108 173 181 17959232 10.1016/j.ygyno.2007.09.016 1:CAS:528:DC%2BD1cXhtlSitA%3D%3D
22. I Nicoletti G Migliorati MC Pagliacci F Grignani C Riccardi 1991 A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol Methods 139 271 279 1710634 10.1016/0022-1759(91) 90198-O 1:CAS:528:DyaK3MXltlenu7Y%3D
23. W Matsui, et al. 2005 Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia Br J Haematol 128 853 862 15755292 10.1111/j.1365-2141.2005.05395.x 1:CAS:528:DC%2BD2MXjt1Cltb8%3D
24. YD Yoo, et al. 2004 The human myotubularin-related protein suppresses the growth of lung carcinoma cells Oncol Rep 12 667 671 15289854 1:CAS:528:DC%2BD2cXnt1entL0%3D
25. DG Popovich DD Kitts 2004 Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines, Int-407 and Caco-2 Can J Physiol Pharmacol 82 183 190 15052284 10.1139/y04-001 1:CAS:528:DC%2BD2cXjtVamtb8%3D
26. EA Bae MJ Han MK Choo SY Park DH Kim 2002 Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities Biol Pharm Bull 25 58 63 11824558 10.1248/bpb.25.58 1:CAS:528:DC%2BD38XhvVehtw%3D%3D
27. H Hasegawa 2004 Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid J Pharmacol Sci 95 153 157 15215638 10.1254/jphs.FMJ04001X4 1:CAS:528:DC%2BD2cXltlGksLs%3D
28. W Wang, et al. 2008 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action Br J Cancer 98 792 802 18253123 10.1038/sj.bjc.6604227 1:STN:280:DC%2BD1c7itFyqsw%3D%3D
29. FF Arantes, et al. 2009 Synthesis and cytotoxic activity of alpha-santonin derivatives Eur J Med Chem 44 3739 3745 19406535 10.1016/j.ejmech.2009.03.036 1:CAS:528:DC%2BD1MXoslGhsL4%3D
30. Henke G, et al. Pharmacokinetics and biodistribution of Erufosine in nude mice-implications for combination with radiotherapy. Radiat Oncol 2009;4:46.
31. W Wang ER Rayburn Y Zhao H Wang R Zhang 2009 Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action Cancer Lett 278 241 248 19203832 10.1016/j.canlet.2009.01.005 1:CAS:528:DC%2BD1MXltVCqs7w%3D
32. J Yan D Luo Y Luo X Gao G Zhang 2006 Induction of G1 arrest and differentiation in MDA-MB-231 breast cancer cell by boehmeriasin A, a novel compound from plant Int J Gynecol Cancer 16 165 170 16445628 10.1111/j.1525-1438.2006.00291.x 1:STN:280:DC%2BD28%2FmtF2ntg%3D%3D
33. ME Huang, et al. 1988 Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood 72 567 572 3165295 1:STN:280: DyaL1c3psVeisg%3D%3D
34. AK Taraphdar M Roy RK Bhattacharya 2001 Natural products as inducers of apoptosis: implication for cancer therapy and prevention Curr Sci 80 1387 1396 1:CAS:528:DC%2BD3MXkvF2ltLY%3D
35. RW Craig OS Frankfurt H Sakagami K Takeda A Bloch 1984 Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells Cancer Res 44 2421 2429 6586286 1:CAS:528:DyaL2cXktFKqtLs%3D
36. CV Cox, et al. 2004 Characterization of acute lymphoblastic leukemia progenitor cells Blood 104 2919 2925 15242869 10.1182/blood-2004-03-0901 1:CAS:528:DC%2BD2cXhtVagu73J
37. K Tsuganezawa, et al. 1998 Flow cytometric diagnosis of the cell lineage and developmental stage of acute lymphoblastic leukemia by novel monoclonal antibodies specific to human pre-B-cell receptor Blood 92 4317 4324 9834238 1:CAS:528:DyaK1cXnslyltr4%3D
38. L Herrera S Yarbrough V Ghetie DB Aquino ES Vitetta 2003 Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins Leukemia 17 334 338 12592332 10.1038/sj.leu.2402790 1:CAS:528: DC%2BD3sXht1Glt7c%3D
39. DC Otero AN Anzelon RC Rickert 2003 CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals J Immunol 170 1 73 83 12496385 1:CAS:528:DC%2BD3sXhtFGlug%3D%3D
40. DR Anderson A Grillo-López C Varns KS Chambers N Hanna 1997 Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma Biochem Soc Trans 25 705 708 9191187 1:CAS:528:DyaK2sXjs1ant7w%3D
41. DG Maloney 1998 Advances in immunotherapy of hematologic malignancies Curr Opin Hematol 5 237 243 9747629 10.1097/00062752-199807000-00002 1:STN:280:DyaK1cvhvVCjsw%3D%3D
42. MR Loken VO Shah Z Hollander CI Civin 1988 Flow cytometric analysis of normal B lymphoid development Pathol Immunopathol Res 7 357 370 3266012 10.1159/000157129 1:STN:280:DyaL1M7mtVKhug%3D%3D
43. R Schwartz-Albiez B Dorken DA Monner G Moldenhauer 1991 CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion Int Immunol 3 623 633 1716973 10.1093/intimm/3.7.623 1:STN:280:DyaK38%2FgtFOhtQ%3D%3D
44. A al-Katib RM Mohammad K Khan, et al. 1993 Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh J Immunother Emphasis Tumor Immunol 14 33 42 8399068 1:CAS:528:DyaK2cXis1Slurg%3D
45. NR Wall RM Mohammad AM Al-Katib 2001 Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh Cell Growth Differ 12 641 647 11751459 1:CAS:528:DC%2BD38Xhsl2mtw%3D%3D